Imigrane

Sumatriptan succinate, the active ingredient in Imigrane, is a Triptan (5‑HT1B/1D receptor agonist) presented as a subcutaneous injection solution for subcutaneous use. It treats acute migraine attacks with or without aura in adults, providing rapid relief of headache and associated symptoms.

GNH USA supplies Imigrane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigrane (sumatriptan succinate) is a Triptan used in the acute treatment of migraine.

- Migraine with aura: provides rapid relief of headache, nausea, photophobia and phonophobia. - Migraine without aura: reduces pain intensity and associated migraine symptoms. - Acute migraine attacks (with or without aura): enables patients to regain functional ability quickly.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Tingling or numbness: transient paresthesia in the face or extremities. - Warmth or flushing: sensation of heat or redness. - Chest discomfort: mild pressure or tightness. - Dizziness: light‑headed feeling.

Serious or Rare Side Effects: - Cardiovascular events: myocardial infarction, stroke, or severe hypertension. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity. - Severe allergic reactions: anaphylaxis, angioedema. - Pulmonary edema: fluid accumulation in the lungs.

Before using Imigrane, consider the following precautions: - Cardiovascular disease: avoid in patients with uncontrolled hypertension, coronary artery disease, or prior stroke. - Medication overuse: monitor frequency of use to prevent rebound headaches. - Drug interactions: review concomitant serotonergic agents for serotonin syndrome risk. - Pregnancy and lactation: use only if the potential benefit outweighs the potential risk. - Renal or hepatic impairment: exercise caution and assess individual patient factors. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Imigrane may interact with several medications.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - SSRIs, SNRIs, or other serotonergic drugs: heightened serotonin toxicity. - Ergot alkaloids: additive vasoconstrictive effects. - Other triptans: concurrent use can cause excessive vasoconstriction.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance hypotensive response. - CYP3A4 inhibitors (e.g., ketoconazole): may raise sumatriptan plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may reduce therapeutic efficacy.